Molecular profiling of post-menopausal women with breast cancer on Neoadjuvant Endocrine Therapy with tamoxifen or exemestane

ISRCTN ISRCTN87408408
DOI https://doi.org/10.1186/ISRCTN87408408
Secondary identifying numbers 2
Submission date
12/12/2006
Registration date
26/01/2007
Last edited
27/05/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

http://www.cancerhelp.org.uk/trials/trials-search/trial-tamoxifen-exemestane-postmenopausal-women-breast-cancer-monet

Contact information

Dr Helena Earl
Scientific

Lecturer and Honorary Consultant
Department of Oncology
Box 193, Oncology Canter
Addenbrooke's Hospital
Hills Road
Cambridge
CB2 2QQ
United Kingdom

Phone +44 (0)1223 336800

Study information

Study designRandomised phase II open-label translational study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study acronymMoNET
Study objectivesNeoadjuvant (or primary) endocrine therapy is an ideal platform for predictive or prognostic marker discovery. Although neoadjuvant and adjuvant endocrine therapy are both well-established treatments, their molecular basis remains incompletely understood. There are no predictive or prognostic markers except oestrogen receptor status that can be used to tailor treatment. This study will use neoadjuvant setting as a basis to identify molecular markers of sensitivity and resistance.

On 22/02/2011 the anticipated end date for this trial was updated from 01/01/2010 to 01/05/2011.
Ethics approval(s)Cambridge Local Research Ethics Committee, 21/05/2006
Health condition(s) or problem(s) studiedLocalised or locally advanced early breast cancer
InterventionPatients will be given 16 weeks of neoadjuvant endocrine therapy with tamoxifen (20 mg orally [PO]) or exemestane (25 mg PO) and would have tumour biopsies taken pre-treatment, at the midpoint and a sample taken at the end of treatment for molecular marker studies.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II
Drug / device / biological / vaccine name(s)Tamoxifen, exemestane
Primary outcome measureIdentify molecular markers that would predict the response or resistance to endocrine therapy with exemestane or tamoxifen.
Secondary outcome measures1. Clinical Response Rate (cRR)
2. Radiological Response Rate (rRR)
3. Changes in Ki67 counts in response to therapy
4. Clinical/radiological response among patients over-expressing Epidermal Growth Factor Receptor (EGFR)/Human Epidermal growth factor Receptor 2 (HER-2)
5. Serum levels of Vascular Endothelial Growth Factor Receptors (VEGF-R) and Vascular Endothelial Growth Factor (VEGF) before, during and after treatment
6. Serum circulatory HER-2 Extracellular Domain (ECD) and Circulating Endothelial Cells (CEC) changes during treatment
7. Vascular Endothelial Growth Factor A (VEGFA), Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) and Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) expression and correlation with clinical outcomes
8. Cadherin-11, transcription factor (Activating Protein–1 [AP-1], Ets-2, cyclin D1)
9. Gene profiling to identify molecular markers of response or resistance
Overall study start date01/01/2007
Completion date01/05/2011

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexFemale
Target number of participants100
Key inclusion criteria1. Women with histological diagnosis of primary invasive breast cancer on core biopsy
2. Not a candidate for chemotherapy
3. Localised or locally advanced breast cancer
4. Ultrasound size at least 2 cm:
a. unifocal tumour:
i. T2 or T3 tumours (radiological size more than 20 mm)
ii. T4 tumour of any size with direct extension to either chest wall or skin
iii. inflammatory carcinoma with tumour of any size
OR
b. other locally advanced disease:
i. clinical and radiological involvement of axillary lymph node (radiological diameter more than 20 mm) and primary breast tumour of any diameter
ii. where no primary breast tumour was found, the presence of breast cancer in a Lymph Node (LN) must be histopathologically confirmed by LN biopsy (Tru-cut or whole LN)
OR
c. multifocal tumour:
i. the sum of the tumour diameters must be more than 20 mm (radiological size more than 20 mm)
ii. patients with bilateral disease are eligible to enter the trial
iii. no previous treatment for breast cancer
5. Oestrogen Receptor (ER) positive (Allred score more than or equal to four)
6. Palpable and measurable disease in the breast or axilla
7. Post-menopausal defined by following criteria: cessation of menstrual periods for at least 1 year or bilateral surgical oophorectomy or Follicular Stimulating Hormone (FSH) and oestradiol in the post-menopausal range
8. At least 2 weeks since prior hormone replacement therapy or phyto-oestrogens herbal, alternative, or Over-The Counter (OTC) sex hormone remedies and not on concomitant hormonal therapy with these agents
9. Eastern Cooperative Oncology Group (ECOG) performance status zero, one or two
10. Randomisation and treatment within 4 weeks of biopsy
11. Patient must have adequate bone marrow, hepatic and renal function
12. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
13. Written consent for the trial
Key exclusion criteria1. Patient unfit to receive endocrine-based therapy
2. Previous history of cancer excluding basal cell carcinoma, cervical carcinoma in-situ, or ductal carcinoma in situ of the breast
3. Previous deep vein thrombosis or pulmonary embolism
Date of first enrolment01/01/2007
Date of final enrolment01/05/2011

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Lecturer and Honorary Consultant
Cambridge
CB2 2QQ
United Kingdom

Sponsor information

Cambridge University Hospitals NHS Trust (UK)
Hospital/treatment centre

Addenbrooke's Hospital
Hills Road
Cambridge
CB2 2QQ
England
United Kingdom

ROR logo "ROR" https://ror.org/04v54gj93

Funders

Funder type

Industry

Cambridge University Hospitals NHS Foundation Trust (UK)

No information available

Pfizer Limited (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan